Notice: This company has been marked as potentially delisted and may not be actively trading. Gemphire Therapeutics (GEMP) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends GEMP vs. LPTX, XBIT, ATOS, ANRO, IVA, NVCT, VERU, INZY, ENTA, and IGMSShould you be buying Gemphire Therapeutics stock or one of its competitors? The main competitors of Gemphire Therapeutics include Leap Therapeutics (LPTX), XBiotech (XBIT), Atossa Therapeutics (ATOS), Alto Neuroscience (ANRO), Inventiva (IVA), Nuvectis Pharma (NVCT), Veru (VERU), Inozyme Pharma (INZY), Enanta Pharmaceuticals (ENTA), and IGM Biosciences (IGMS). These companies are all part of the "medical" sector. Gemphire Therapeutics vs. Leap Therapeutics XBiotech Atossa Therapeutics Alto Neuroscience Inventiva Nuvectis Pharma Veru Inozyme Pharma Enanta Pharmaceuticals IGM Biosciences Leap Therapeutics (NASDAQ:LPTX) and Gemphire Therapeutics (NASDAQ:GEMP) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, community ranking, analyst recommendations, risk, institutional ownership, earnings, media sentiment and valuation. Does the media refer more to LPTX or GEMP? In the previous week, Leap Therapeutics had 3 more articles in the media than Gemphire Therapeutics. MarketBeat recorded 3 mentions for Leap Therapeutics and 0 mentions for Gemphire Therapeutics. Leap Therapeutics' average media sentiment score of 0.61 beat Gemphire Therapeutics' score of 0.00 indicating that Leap Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Leap Therapeutics Positive Gemphire Therapeutics Neutral Which has stronger earnings and valuation, LPTX or GEMP? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLeap TherapeuticsN/AN/A-$81.41M-$1.93-1.27Gemphire TherapeuticsN/AN/A-$23.64MN/AN/A Which has more volatility and risk, LPTX or GEMP? Leap Therapeutics has a beta of 0.17, indicating that its stock price is 83% less volatile than the S&P 500. Comparatively, Gemphire Therapeutics has a beta of 2.82, indicating that its stock price is 182% more volatile than the S&P 500. Is LPTX or GEMP more profitable? Leap Therapeutics' return on equity of -116.24% beat Gemphire Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Leap TherapeuticsN/A -116.24% -93.18% Gemphire Therapeutics N/A -419.70%-173.05% Do analysts rate LPTX or GEMP? Leap Therapeutics currently has a consensus target price of $7.50, suggesting a potential upside of 204.88%. Given Leap Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Leap Therapeutics is more favorable than Gemphire Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Leap Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Gemphire Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do insiders & institutionals believe in LPTX or GEMP? 30.5% of Leap Therapeutics shares are held by institutional investors. Comparatively, 17.5% of Gemphire Therapeutics shares are held by institutional investors. 5.4% of Leap Therapeutics shares are held by insiders. Comparatively, 22.7% of Gemphire Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the MarketBeat Community prefer LPTX or GEMP? Leap Therapeutics received 5 more outperform votes than Gemphire Therapeutics when rated by MarketBeat users. However, 69.98% of users gave Gemphire Therapeutics an outperform vote while only 69.01% of users gave Leap Therapeutics an outperform vote. CompanyUnderperformOutperformLeap TherapeuticsOutperform Votes29469.01% Underperform Votes13230.99% Gemphire TherapeuticsOutperform Votes28969.98% Underperform Votes12430.02% SummaryLeap Therapeutics beats Gemphire Therapeutics on 9 of the 13 factors compared between the two stocks. Get Gemphire Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GEMP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GEMP vs. The Competition Export to ExcelMetricGemphire TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$29.15M$6.55B$5.36B$9.13BDividend YieldN/A2.96%5.37%4.00%P/E RatioN/A6.7974.7215.64Price / SalesN/A353.051,287.0785.06Price / CashN/A22.7136.3232.99Price / Book3.635.084.974.69Net Income-$23.64M$154.90M$117.89M$224.57M Gemphire Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GEMPGemphire TherapeuticsN/A$1.96+0.8%N/A-41.6%$29.15MN/A0.009LPTXLeap Therapeutics1.7357 of 5 stars$3.10+1.3%$7.50+141.9%-22.9%$118.79M$1.50M-1.6140XBITXBiotech0.588 of 5 stars$3.85-0.8%N/A-17.6%$117.36M$4.01M-3.56100ATOSAtossa Therapeutics1.2039 of 5 stars$0.92+2.3%$7.00+656.9%+6.1%$116.34MN/A-4.208ANROAlto Neuroscience2.5878 of 5 stars$4.28-1.6%$20.00+367.3%N/A$115.43M$210,000.000.00N/AGap DownIVAInventiva2.6256 of 5 stars$2.17flat$13.25+510.6%-43.3%$113.88M$15.62M0.00100Positive NewsNVCTNuvectis Pharma2.9877 of 5 stars$5.81flat$21.00+261.4%-30.3%$112.26MN/A-5.018Positive NewsVERUVeru2.559 of 5 stars$0.76-2.5%$4.00+424.8%+194.6%$111.57M$16.89M-1.59230Options VolumeGap UpINZYInozyme Pharma3.3838 of 5 stars$1.72-14.0%$18.33+965.9%-68.7%$110.49MN/A-1.1050ENTAEnanta Pharmaceuticals4.4057 of 5 stars$5.03-1.2%$17.25+242.9%-56.3%$106.61M$67.64M-0.92160Positive NewsGap DownIGMSIGM Biosciences4.7047 of 5 stars$1.78-14.8%$5.50+209.0%-83.7%$105.85M$2.92M-0.49190 Related Companies and Tools Related Companies Leap Therapeutics Competitors XBiotech Competitors Atossa Therapeutics Competitors Alto Neuroscience Competitors Inventiva Competitors Nuvectis Pharma Competitors Veru Competitors Inozyme Pharma Competitors Enanta Pharmaceuticals Competitors IGM Biosciences Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GEMP) was last updated on 1/22/2025 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump currency shock imminentTrump's Quiet $1.9 Trillion Move Against the Fed A small army of Americans, with Trump's support, has launc...Stansberry Research | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gemphire Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Gemphire Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GEMP Stock Alerts